Article Information
History
- June 3, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Kristen Hansen, PhD*,1,
- Steve R. Makkar, PhD*,1,
- David Sahner, MD1,
- Josh Fessel, MD PhD1,
- Nathan Hotaling, PhD1,
- Hythem Sidky, PhD†,1 and
- the N3C Consortium
- 1National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
- ↵†Corresponding author. hythem.sidky{at}nih.gov National Center for Advancing Translational Sciences 6701 Democracy Boulevard Bethesda, MD 20892
↵* These authors contributed equally
Posted June 03, 2023.
Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study
